An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Veracyte, Inc. (Nasdaq: VCYT) will release its first quarter 2024 financial results on May 7, 2024, followed by a conference call and webcast to discuss the results and provide a business update.
Veracyte, Inc. (Nasdaq: VCYT) pubblicherà i risultati finanziari del primo trimestre del 2024 il 7 maggio 2024, seguiti da una conferenza telefonica e un webcast per discutere i risultati e fornire un aggiornamento aziendale.
Veracyte, Inc. (Nasdaq: VCYT) anunciará los resultados financieros del primer trimestre de 2024 el 7 de mayo de 2024, seguido por una conferencia telefónica y una transmisión web para discutir los resultados y proporcionar una actualización del negocio.
Veracyte, Inc. (나스닥: VCYT)는 2024년 5월 7일에 2024년 첫 번째 분기 재무 결과를 발표할 예정이며, 그 결과를 논의하고 비즈니스 업데이트를 제공하기 위해 컨퍼런스 콜과 웹캐스트를 진행할 것입니다.
Veracyte, Inc. (Nasdaq: VCYT) publiera ses résultats financiers pour le premier trimestre 2024 le 7 mai 2024, suivis d'une conférence téléphonique et d'un webcast pour discuter des résultats et fournir une mise à jour de l'entreprise.
Veracyte, Inc. (Nasdaq: VCYT) wird am 7. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 veröffentlichen, gefolgt von einer Telefonkonferenz und einem Webcast, um die Ergebnisse zu diskutieren und ein Geschäftsupdate zu geben.
Positive
None.
Negative
None.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, May 7, 2024. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.
Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).
When will Veracyte release its first quarter 2024 financial results?
Veracyte will release its first quarter 2024 financial results on May 7, 2024.
What is the ticker symbol for Veracyte, Inc.?
The ticker symbol for Veracyte, Inc. is VCYT.
What time will the conference call to discuss the financial results take place?
The conference call to discuss the financial results will take place at 4:30 p.m. Eastern Time on May 7, 2024.
Where can I access the webcast of the conference call?
The webcast of the conference call can be accessed live from the company's website at the following link: https://edge.media-server.com/mmc/p/6m9ec99y.
Will there be a replay of the webcast available?
Yes, a webcast replay will be available on the company's website following the conclusion of the live broadcast.
veracyte is a pioneering genomic diagnostics company. our tests are dramatically improving clinical outcomes for patients by resolving inconclusive results from traditional diagnostic methods. we ask the right questions to resolve ambiguity and bring assurance to light, rendering tens of thousands of costly and unnecessary surgeries truly unnecessary. we are giving patients a clearer path forward. through scientific rigor we employ the best tools, best science and best minds to create tests that enable a more accurate diagnosis without the need for risky, costly and often unnecessary surgery. veracyte consistently brings to bear evidence that is unprecedented in genomic tests, thereby changing today's clinical practice standards. we are making a difference in the lives of physicians and patients. we are doing something real. .
